Format

Send to

Choose Destination
J Tissue Eng Regen Med. 2017 Jul;11(7):2081-2089. doi: 10.1002/term.2104. Epub 2015 Dec 9.

Scaffold-cell bone engineering in a validated preclinical animal model: precursors vs differentiated cell source.

Author information

1
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
2
Department of Trauma Surgery, University of Regensburg, Germany.
3
Department of Orthopaedics and Accident Surgery, Waldkrankenhaus Protestant Hospital, Berlin, Germany.

Abstract

The properties of osteoblasts (OBs) isolated from the axial skeleton (tOBs) differ from OBs of the orofacial skeleton (mOBs) due to the different embryological origins of the bones. The aim of the study was to assess and compare the regenerative potential of allogenic bone marrow-derived mesenchymal progenitor cells with allogenic tOBs and allogenic mOBs in combination with a mPCL-TCP scaffold in critical-sized segmental bone defects in sheep tibiae. After 6 months, the tibiae were explanted and underwent biomechanical testing, micro-computed tomography (microCT) and histological and immunohistochemical analyses. Allogenic MPCs demonstrated a trend towards a better outcome in biomechanical testing and the mean values of newly formed bone. Biomechanical, microCT and histological analysis showed no significant differences in the bone regeneration potential of tOBs and mOBs in our in vitro study, as well as in the bone regeneration potential of different cell types in vivo.

KEYWORDS:

allogenic cells; bone defect; bone regeneration; bone tissue engineering; mesenchymal progenitor cells; osteoblasts; polycaprolactone; scaffolds

PMID:
26648044
DOI:
10.1002/term.2104
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center